nodes	percent_of_prediction	percent_of_DWPC	metapath
Floxuridine—Ischaemia—Sorafenib—thyroid cancer	0.0317	0.0469	CcSEcCtD
Floxuridine—Cholecystitis—Vandetanib—thyroid cancer	0.0298	0.0441	CcSEcCtD
Floxuridine—Zidovudine—TERT—thyroid cancer	0.0298	1	CrCbGaD
Floxuridine—TYMS—Retinoblastoma (RB) in Cancer—CCDC6—thyroid cancer	0.0281	0.155	CbGpPWpGaD
Floxuridine—Nail disorder—Vandetanib—thyroid cancer	0.0264	0.0391	CcSEcCtD
Floxuridine—Cholecystitis—Sorafenib—thyroid cancer	0.0201	0.0298	CcSEcCtD
Floxuridine—TYMS—Erlotinib—Vandetanib—thyroid cancer	0.0201	0.449	CbGdCrCtD
Floxuridine—Embolism—Sorafenib—thyroid cancer	0.018	0.0266	CcSEcCtD
Floxuridine—TYMP—Fluoropyrimidine Activity—SMUG1—thyroid cancer	0.0178	0.0981	CbGpPWpGaD
Floxuridine—TYMS—G1/S-Specific Transcription—CDK1—thyroid cancer	0.015	0.0826	CbGpPWpGaD
Floxuridine—TYMP—saliva-secreting gland—thyroid cancer	0.0149	0.217	CbGeAlD
Floxuridine—Myocardial ischaemia—Sorafenib—thyroid cancer	0.0144	0.0213	CcSEcCtD
Floxuridine—Gastroenteritis—Vandetanib—thyroid cancer	0.014	0.0208	CcSEcCtD
Floxuridine—TYMS—Afatinib—Vandetanib—thyroid cancer	0.0131	0.294	CbGdCrCtD
Floxuridine—Lethargy—Vandetanib—thyroid cancer	0.0127	0.0188	CcSEcCtD
Floxuridine—Glossitis—Sorafenib—thyroid cancer	0.0125	0.0186	CcSEcCtD
Floxuridine—TYMP—trachea—thyroid cancer	0.0115	0.167	CbGeAlD
Floxuridine—TYMS—Gefitinib—Vandetanib—thyroid cancer	0.0115	0.257	CbGdCrCtD
Floxuridine—Dry skin—Vandetanib—thyroid cancer	0.0114	0.0169	CcSEcCtD
Floxuridine—Gastritis—Vandetanib—thyroid cancer	0.011	0.0163	CcSEcCtD
Floxuridine—TYMP—Bladder Cancer—BRAF—thyroid cancer	0.0103	0.057	CbGpPWpGaD
Floxuridine—Photosensitivity reaction—Vandetanib—thyroid cancer	0.00981	0.0145	CcSEcCtD
Floxuridine—Stomatitis—Vandetanib—thyroid cancer	0.00934	0.0138	CcSEcCtD
Floxuridine—TYMS—Fluoropyrimidine Activity—SMUG1—thyroid cancer	0.0091	0.0502	CbGpPWpGaD
Floxuridine—TYMP—thyroid gland—thyroid cancer	0.0091	0.132	CbGeAlD
Floxuridine—Epistaxis—Vandetanib—thyroid cancer	0.00904	0.0134	CcSEcCtD
Floxuridine—TYMS—E2F mediated regulation of DNA replication—CDK1—thyroid cancer	0.00881	0.0486	CbGpPWpGaD
Floxuridine—Haemoglobin—Vandetanib—thyroid cancer	0.00864	0.0128	CcSEcCtD
Floxuridine—Haemorrhage—Vandetanib—thyroid cancer	0.0086	0.0127	CcSEcCtD
Floxuridine—TYMP—head—thyroid cancer	0.00807	0.117	CbGeAlD
Floxuridine—TYMS—thyroid gland—thyroid cancer	0.00781	0.113	CbGeAlD
Floxuridine—Dry skin—Sorafenib—thyroid cancer	0.00769	0.0114	CcSEcCtD
Floxuridine—Alopecia—Vandetanib—thyroid cancer	0.0076	0.0113	CcSEcCtD
Floxuridine—TYMP—Bladder Cancer—CCND1—thyroid cancer	0.00754	0.0416	CbGpPWpGaD
Floxuridine—Gastritis—Sorafenib—thyroid cancer	0.00742	0.011	CcSEcCtD
Floxuridine—Lacrimation—Epirubicin—thyroid cancer	0.00726	0.0108	CcSEcCtD
Floxuridine—Muscle spasms—Vandetanib—thyroid cancer	0.0072	0.0107	CcSEcCtD
Floxuridine—TYMS—head—thyroid cancer	0.00693	0.101	CbGeAlD
Floxuridine—Lacrimation—Doxorubicin—thyroid cancer	0.00672	0.00995	CcSEcCtD
Floxuridine—Embolism—Epirubicin—thyroid cancer	0.00665	0.00985	CcSEcCtD
Floxuridine—Nail disorder—Epirubicin—thyroid cancer	0.00658	0.00975	CcSEcCtD
Floxuridine—Stomatitis—Sorafenib—thyroid cancer	0.0063	0.00933	CcSEcCtD
Floxuridine—Embolism—Doxorubicin—thyroid cancer	0.00615	0.00911	CcSEcCtD
Floxuridine—Epistaxis—Sorafenib—thyroid cancer	0.0061	0.00902	CcSEcCtD
Floxuridine—Nail disorder—Doxorubicin—thyroid cancer	0.00609	0.00902	CcSEcCtD
Floxuridine—Infection—Vandetanib—thyroid cancer	0.00607	0.00899	CcSEcCtD
Floxuridine—Nervous system disorder—Vandetanib—thyroid cancer	0.00599	0.00887	CcSEcCtD
Floxuridine—Thrombocytopenia—Vandetanib—thyroid cancer	0.00598	0.00886	CcSEcCtD
Floxuridine—Nystagmus—Epirubicin—thyroid cancer	0.00598	0.00885	CcSEcCtD
Floxuridine—Haemoglobin—Sorafenib—thyroid cancer	0.00583	0.00863	CcSEcCtD
Floxuridine—Haemorrhage—Sorafenib—thyroid cancer	0.0058	0.00859	CcSEcCtD
Floxuridine—TYMP—lymph node—thyroid cancer	0.00565	0.0821	CbGeAlD
Floxuridine—Nystagmus—Doxorubicin—thyroid cancer	0.00553	0.00819	CcSEcCtD
Floxuridine—Abscess—Epirubicin—thyroid cancer	0.0054	0.00799	CcSEcCtD
Floxuridine—Decreased appetite—Vandetanib—thyroid cancer	0.00531	0.00786	CcSEcCtD
Floxuridine—Alopecia—Sorafenib—thyroid cancer	0.00513	0.00759	CcSEcCtD
Floxuridine—Erythema—Sorafenib—thyroid cancer	0.00505	0.00748	CcSEcCtD
Floxuridine—Gastrointestinal pain—Vandetanib—thyroid cancer	0.005	0.0074	CcSEcCtD
Floxuridine—Abscess—Doxorubicin—thyroid cancer	0.00499	0.00739	CcSEcCtD
Floxuridine—TYMP—Bladder Cancer—TP53—thyroid cancer	0.00497	0.0274	CbGpPWpGaD
Floxuridine—Muscle spasms—Sorafenib—thyroid cancer	0.00486	0.00719	CcSEcCtD
Floxuridine—TYMS—lymph node—thyroid cancer	0.00485	0.0705	CbGeAlD
Floxuridine—Abdominal pain—Vandetanib—thyroid cancer	0.00483	0.00715	CcSEcCtD
Floxuridine—Body temperature increased—Vandetanib—thyroid cancer	0.00483	0.00715	CcSEcCtD
Floxuridine—TYMS—Circadian rythm related genes—NKX2-1—thyroid cancer	0.00475	0.0262	CbGpPWpGaD
Floxuridine—TYMP—Bladder Cancer—HRAS—thyroid cancer	0.00475	0.0262	CbGpPWpGaD
Floxuridine—TYMP—Fluoropyrimidine Activity—TP53—thyroid cancer	0.00472	0.026	CbGpPWpGaD
Floxuridine—Anaemia—Sorafenib—thyroid cancer	0.00467	0.00691	CcSEcCtD
Floxuridine—TYMS—E2F transcription factor network—CDK1—thyroid cancer	0.00467	0.0257	CbGpPWpGaD
Floxuridine—Lacrimation increased—Epirubicin—thyroid cancer	0.00463	0.00686	CcSEcCtD
Floxuridine—Glossitis—Epirubicin—thyroid cancer	0.00463	0.00686	CcSEcCtD
Floxuridine—Leukopenia—Sorafenib—thyroid cancer	0.00452	0.00669	CcSEcCtD
Floxuridine—Asthenia—Vandetanib—thyroid cancer	0.00438	0.00649	CcSEcCtD
Floxuridine—Glossitis—Doxorubicin—thyroid cancer	0.00429	0.00635	CcSEcCtD
Floxuridine—Lacrimation increased—Doxorubicin—thyroid cancer	0.00429	0.00635	CcSEcCtD
Floxuridine—Diarrhoea—Vandetanib—thyroid cancer	0.00418	0.00619	CcSEcCtD
Floxuridine—Anaphylactic shock—Sorafenib—thyroid cancer	0.00412	0.0061	CcSEcCtD
Floxuridine—Infection—Sorafenib—thyroid cancer	0.00409	0.00606	CcSEcCtD
Floxuridine—TYMS—Retinoblastoma (RB) in Cancer—CDK1—thyroid cancer	0.00405	0.0224	CbGpPWpGaD
Floxuridine—Nervous system disorder—Sorafenib—thyroid cancer	0.00404	0.00598	CcSEcCtD
Floxuridine—Thrombocytopenia—Sorafenib—thyroid cancer	0.00404	0.00597	CcSEcCtD
Floxuridine—Anorexia—Sorafenib—thyroid cancer	0.00393	0.00582	CcSEcCtD
Floxuridine—Vomiting—Vandetanib—thyroid cancer	0.00388	0.00575	CcSEcCtD
Floxuridine—Rash maculo-papular—Epirubicin—thyroid cancer	0.00388	0.00575	CcSEcCtD
Floxuridine—Rash—Vandetanib—thyroid cancer	0.00385	0.0057	CcSEcCtD
Floxuridine—Dermatitis—Vandetanib—thyroid cancer	0.00385	0.0057	CcSEcCtD
Floxuridine—Headache—Vandetanib—thyroid cancer	0.00383	0.00567	CcSEcCtD
Floxuridine—Nausea—Vandetanib—thyroid cancer	0.00363	0.00537	CcSEcCtD
Floxuridine—Rash maculo-papular—Doxorubicin—thyroid cancer	0.00359	0.00532	CcSEcCtD
Floxuridine—Decreased appetite—Sorafenib—thyroid cancer	0.00358	0.0053	CcSEcCtD
Floxuridine—Thrombophlebitis—Epirubicin—thyroid cancer	0.00358	0.0053	CcSEcCtD
Floxuridine—Photosensitivity—Epirubicin—thyroid cancer	0.00353	0.00523	CcSEcCtD
Floxuridine—TYMS—G1/S Transition—CDK1—thyroid cancer	0.00339	0.0187	CbGpPWpGaD
Floxuridine—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00337	0.00499	CcSEcCtD
Floxuridine—Thrombophlebitis—Doxorubicin—thyroid cancer	0.00331	0.0049	CcSEcCtD
Floxuridine—Photosensitivity—Doxorubicin—thyroid cancer	0.00327	0.00484	CcSEcCtD
Floxuridine—Abdominal pain—Sorafenib—thyroid cancer	0.00326	0.00482	CcSEcCtD
Floxuridine—Body temperature increased—Sorafenib—thyroid cancer	0.00326	0.00482	CcSEcCtD
Floxuridine—Lethargy—Epirubicin—thyroid cancer	0.00316	0.00468	CcSEcCtD
Floxuridine—TYMP—Metabolism—MINPP1—thyroid cancer	0.00313	0.0173	CbGpPWpGaD
Floxuridine—Hypersensitivity—Sorafenib—thyroid cancer	0.00304	0.0045	CcSEcCtD
Floxuridine—Asthenia—Sorafenib—thyroid cancer	0.00296	0.00438	CcSEcCtD
Floxuridine—Lethargy—Doxorubicin—thyroid cancer	0.00293	0.00433	CcSEcCtD
Floxuridine—TYMS—Mitotic G1-G1/S phases—CDK1—thyroid cancer	0.00285	0.0157	CbGpPWpGaD
Floxuridine—Dry skin—Epirubicin—thyroid cancer	0.00284	0.00421	CcSEcCtD
Floxuridine—Diarrhoea—Sorafenib—thyroid cancer	0.00282	0.00418	CcSEcCtD
Floxuridine—Gastritis—Epirubicin—thyroid cancer	0.00274	0.00406	CcSEcCtD
Floxuridine—TYMP—Metabolism—NDUFA13—thyroid cancer	0.00266	0.0147	CbGpPWpGaD
Floxuridine—Dry skin—Doxorubicin—thyroid cancer	0.00263	0.00389	CcSEcCtD
Floxuridine—Vomiting—Sorafenib—thyroid cancer	0.00262	0.00388	CcSEcCtD
Floxuridine—Angina pectoris—Epirubicin—thyroid cancer	0.00261	0.00386	CcSEcCtD
Floxuridine—Rash—Sorafenib—thyroid cancer	0.0026	0.00385	CcSEcCtD
Floxuridine—Dermatitis—Sorafenib—thyroid cancer	0.0026	0.00384	CcSEcCtD
Floxuridine—Headache—Sorafenib—thyroid cancer	0.00258	0.00382	CcSEcCtD
Floxuridine—Pancytopenia—Epirubicin—thyroid cancer	0.00254	0.00377	CcSEcCtD
Floxuridine—Gastritis—Doxorubicin—thyroid cancer	0.00254	0.00376	CcSEcCtD
Floxuridine—TYMS—Cell Cycle, Mitotic—PCM1—thyroid cancer	0.00253	0.0139	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—CHST14—thyroid cancer	0.0025	0.0138	CbGpPWpGaD
Floxuridine—Nausea—Sorafenib—thyroid cancer	0.00245	0.00362	CcSEcCtD
Floxuridine—Photosensitivity reaction—Epirubicin—thyroid cancer	0.00244	0.00362	CcSEcCtD
Floxuridine—TYMS—Fluoropyrimidine Activity—TP53—thyroid cancer	0.00242	0.0133	CbGpPWpGaD
Floxuridine—Angina pectoris—Doxorubicin—thyroid cancer	0.00241	0.00357	CcSEcCtD
Floxuridine—Pancytopenia—Doxorubicin—thyroid cancer	0.00235	0.00348	CcSEcCtD
Floxuridine—Stomatitis—Epirubicin—thyroid cancer	0.00233	0.00345	CcSEcCtD
Floxuridine—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.00226	0.00335	CcSEcCtD
Floxuridine—TYMS—Cell Cycle—PCM1—thyroid cancer	0.00226	0.0125	CbGpPWpGaD
Floxuridine—Epistaxis—Epirubicin—thyroid cancer	0.00225	0.00334	CcSEcCtD
Floxuridine—Agranulocytosis—Epirubicin—thyroid cancer	0.00223	0.0033	CcSEcCtD
Floxuridine—Haemoglobin—Epirubicin—thyroid cancer	0.00215	0.00319	CcSEcCtD
Floxuridine—Stomatitis—Doxorubicin—thyroid cancer	0.00215	0.00319	CcSEcCtD
Floxuridine—Haemorrhage—Epirubicin—thyroid cancer	0.00214	0.00317	CcSEcCtD
Floxuridine—Pharyngitis—Epirubicin—thyroid cancer	0.00213	0.00315	CcSEcCtD
Floxuridine—Epistaxis—Doxorubicin—thyroid cancer	0.00208	0.00309	CcSEcCtD
Floxuridine—Agranulocytosis—Doxorubicin—thyroid cancer	0.00206	0.00305	CcSEcCtD
Floxuridine—TYMP—Metabolism—HPGD—thyroid cancer	0.00202	0.0111	CbGpPWpGaD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.00201	0.0111	CbGpPWpGaD
Floxuridine—Haemoglobin—Doxorubicin—thyroid cancer	0.00199	0.00295	CcSEcCtD
Floxuridine—Haemorrhage—Doxorubicin—thyroid cancer	0.00198	0.00294	CcSEcCtD
Floxuridine—Pharyngitis—Doxorubicin—thyroid cancer	0.00197	0.00292	CcSEcCtD
Floxuridine—Alopecia—Epirubicin—thyroid cancer	0.00189	0.00281	CcSEcCtD
Floxuridine—Erythema—Epirubicin—thyroid cancer	0.00187	0.00276	CcSEcCtD
Floxuridine—Muscle spasms—Epirubicin—thyroid cancer	0.00179	0.00266	CcSEcCtD
Floxuridine—Alopecia—Doxorubicin—thyroid cancer	0.00175	0.0026	CcSEcCtD
Floxuridine—Ill-defined disorder—Epirubicin—thyroid cancer	0.00173	0.00256	CcSEcCtD
Floxuridine—Erythema—Doxorubicin—thyroid cancer	0.00173	0.00256	CcSEcCtD
Floxuridine—Anaemia—Epirubicin—thyroid cancer	0.00173	0.00255	CcSEcCtD
Floxuridine—TYMS—Retinoblastoma (RB) in Cancer—CCND1—thyroid cancer	0.00169	0.00932	CbGpPWpGaD
Floxuridine—Malaise—Epirubicin—thyroid cancer	0.00168	0.00249	CcSEcCtD
Floxuridine—Leukopenia—Epirubicin—thyroid cancer	0.00167	0.00247	CcSEcCtD
Floxuridine—Muscle spasms—Doxorubicin—thyroid cancer	0.00166	0.00246	CcSEcCtD
Floxuridine—TYMS—Metabolism—MINPP1—thyroid cancer	0.0016	0.00884	CbGpPWpGaD
Floxuridine—Ill-defined disorder—Doxorubicin—thyroid cancer	0.0016	0.00237	CcSEcCtD
Floxuridine—Anaemia—Doxorubicin—thyroid cancer	0.0016	0.00236	CcSEcCtD
Floxuridine—Discomfort—Epirubicin—thyroid cancer	0.00157	0.00232	CcSEcCtD
Floxuridine—Malaise—Doxorubicin—thyroid cancer	0.00156	0.00231	CcSEcCtD
Floxuridine—Leukopenia—Doxorubicin—thyroid cancer	0.00155	0.00229	CcSEcCtD
Floxuridine—TYMS—Cell Cycle, Mitotic—TPR—thyroid cancer	0.00154	0.00852	CbGpPWpGaD
Floxuridine—Confusional state—Epirubicin—thyroid cancer	0.00154	0.00227	CcSEcCtD
Floxuridine—Anaphylactic shock—Epirubicin—thyroid cancer	0.00152	0.00226	CcSEcCtD
Floxuridine—Infection—Epirubicin—thyroid cancer	0.00151	0.00224	CcSEcCtD
Floxuridine—Nervous system disorder—Epirubicin—thyroid cancer	0.00149	0.00221	CcSEcCtD
Floxuridine—Thrombocytopenia—Epirubicin—thyroid cancer	0.00149	0.00221	CcSEcCtD
Floxuridine—Discomfort—Doxorubicin—thyroid cancer	0.00145	0.00215	CcSEcCtD
Floxuridine—Anorexia—Epirubicin—thyroid cancer	0.00145	0.00215	CcSEcCtD
Floxuridine—Confusional state—Doxorubicin—thyroid cancer	0.00142	0.0021	CcSEcCtD
Floxuridine—Anaphylactic shock—Doxorubicin—thyroid cancer	0.00141	0.00209	CcSEcCtD
Floxuridine—Infection—Doxorubicin—thyroid cancer	0.0014	0.00207	CcSEcCtD
Floxuridine—Nervous system disorder—Doxorubicin—thyroid cancer	0.00138	0.00205	CcSEcCtD
Floxuridine—TYMS—Cell Cycle—TPR—thyroid cancer	0.00138	0.00761	CbGpPWpGaD
Floxuridine—Thrombocytopenia—Doxorubicin—thyroid cancer	0.00138	0.00204	CcSEcCtD
Floxuridine—TYMS—Metabolism—NDUFA13—thyroid cancer	0.00136	0.00752	CbGpPWpGaD
Floxuridine—Anorexia—Doxorubicin—thyroid cancer	0.00134	0.00199	CcSEcCtD
Floxuridine—Decreased appetite—Epirubicin—thyroid cancer	0.00132	0.00196	CcSEcCtD
Floxuridine—TYMS—Metabolism—CHST14—thyroid cancer	0.00128	0.00707	CbGpPWpGaD
Floxuridine—Feeling abnormal—Epirubicin—thyroid cancer	0.00126	0.00186	CcSEcCtD
Floxuridine—Gastrointestinal pain—Epirubicin—thyroid cancer	0.00125	0.00184	CcSEcCtD
Floxuridine—Decreased appetite—Doxorubicin—thyroid cancer	0.00123	0.00181	CcSEcCtD
Floxuridine—TYMS—Circadian rythm related genes—PPARG—thyroid cancer	0.00122	0.00671	CbGpPWpGaD
Floxuridine—Body temperature increased—Epirubicin—thyroid cancer	0.0012	0.00178	CcSEcCtD
Floxuridine—Abdominal pain—Epirubicin—thyroid cancer	0.0012	0.00178	CcSEcCtD
Floxuridine—TYMS—Mitotic G1-G1/S phases—CCND1—thyroid cancer	0.00119	0.00655	CbGpPWpGaD
Floxuridine—Feeling abnormal—Doxorubicin—thyroid cancer	0.00116	0.00172	CcSEcCtD
Floxuridine—TYMP—Metabolism—TPR—thyroid cancer	0.00116	0.0064	CbGpPWpGaD
Floxuridine—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.00115	0.00171	CcSEcCtD
Floxuridine—TYMP—Metabolism—PRKAR1A—thyroid cancer	0.00114	0.00629	CbGpPWpGaD
Floxuridine—Hypersensitivity—Epirubicin—thyroid cancer	0.00112	0.00166	CcSEcCtD
Floxuridine—Abdominal pain—Doxorubicin—thyroid cancer	0.00111	0.00165	CcSEcCtD
Floxuridine—Body temperature increased—Doxorubicin—thyroid cancer	0.00111	0.00165	CcSEcCtD
Floxuridine—TYMS—Retinoblastoma (RB) in Cancer—TP53—thyroid cancer	0.00111	0.00614	CbGpPWpGaD
Floxuridine—Asthenia—Epirubicin—thyroid cancer	0.00109	0.00162	CcSEcCtD
Floxuridine—TYMS—Cell Cycle, Mitotic—CDK1—thyroid cancer	0.00105	0.00577	CbGpPWpGaD
Floxuridine—Diarrhoea—Epirubicin—thyroid cancer	0.00104	0.00154	CcSEcCtD
Floxuridine—Hypersensitivity—Doxorubicin—thyroid cancer	0.00104	0.00154	CcSEcCtD
Floxuridine—TYMS—Metabolism—HPGD—thyroid cancer	0.00103	0.0057	CbGpPWpGaD
Floxuridine—Asthenia—Doxorubicin—thyroid cancer	0.00101	0.0015	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	0.000996	0.0055	CbGpPWpGaD
Floxuridine—Vomiting—Epirubicin—thyroid cancer	0.000968	0.00143	CcSEcCtD
Floxuridine—Diarrhoea—Doxorubicin—thyroid cancer	0.000964	0.00143	CcSEcCtD
Floxuridine—Rash—Epirubicin—thyroid cancer	0.00096	0.00142	CcSEcCtD
Floxuridine—Dermatitis—Epirubicin—thyroid cancer	0.00096	0.00142	CcSEcCtD
Floxuridine—Headache—Epirubicin—thyroid cancer	0.000954	0.00141	CcSEcCtD
Floxuridine—TYMS—Cell Cycle—CDK1—thyroid cancer	0.000936	0.00516	CbGpPWpGaD
Floxuridine—Nausea—Epirubicin—thyroid cancer	0.000905	0.00134	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	0.0009	0.00497	CbGpPWpGaD
Floxuridine—Vomiting—Doxorubicin—thyroid cancer	0.000896	0.00133	CcSEcCtD
Floxuridine—Rash—Doxorubicin—thyroid cancer	0.000889	0.00132	CcSEcCtD
Floxuridine—Dermatitis—Doxorubicin—thyroid cancer	0.000888	0.00131	CcSEcCtD
Floxuridine—Headache—Doxorubicin—thyroid cancer	0.000883	0.00131	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	0.000869	0.00479	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—SLC5A5—thyroid cancer	0.000868	0.00479	CbGpPWpGaD
Floxuridine—Nausea—Doxorubicin—thyroid cancer	0.000837	0.00124	CcSEcCtD
Floxuridine—TYMS—Circadian rythm related genes—PTEN—thyroid cancer	0.000834	0.0046	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—RXRA—thyroid cancer	0.000729	0.00402	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—TERT—thyroid cancer	0.000674	0.00372	CbGpPWpGaD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	0.000667	0.00368	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—TPR—thyroid cancer	0.000593	0.00327	CbGpPWpGaD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	0.000593	0.00327	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—PRKAR1A—thyroid cancer	0.000584	0.00322	CbGpPWpGaD
Floxuridine—TYMS—Circadian rythm related genes—TP53—thyroid cancer	0.000569	0.00314	CbGpPWpGaD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	0.000501	0.00276	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—PPARG—thyroid cancer	0.000461	0.00254	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—SLC5A5—thyroid cancer	0.000444	0.00245	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle, Mitotic—CCND1—thyroid cancer	0.000436	0.0024	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—CCND1—thyroid cancer	0.00039	0.00215	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—RXRA—thyroid cancer	0.000373	0.00206	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—PTGS2—thyroid cancer	0.000362	0.002	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—PTEN—thyroid cancer	0.000316	0.00174	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—TP53—thyroid cancer	0.000257	0.00142	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—PPARG—thyroid cancer	0.000236	0.0013	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—PTGS2—thyroid cancer	0.000185	0.00102	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—AKT1—thyroid cancer	0.000182	0.001	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—PTEN—thyroid cancer	0.000162	0.000891	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—AKT1—thyroid cancer	9.31e-05	0.000514	CbGpPWpGaD
